Ketorolac Tromethamine Injection — Competitive Intelligence Brief

Ketorolac Tromethamine Injection (Ketorolac Tromethamine Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management / Anesthesia.

marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) Pain Management / Anesthesia Small molecule

Target snapshot

Ketorolac Tromethamine Injection (Ketorolac Tromethamine Injection) — UConn Health. Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ketorolac Tromethamine Injection TARGET	Ketorolac Tromethamine Injection	UConn Health	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Nerkardou (5 mg) & (10 mg)	Nerkardou (5 mg) & (10 mg)	Genuine Research Center, Egypt	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-2
Prednisone and Aspirin	Prednisone and Aspirin	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Corticosteroid and nonsteroidal anti-inflammatory drug (NSAID) combination	Glucocorticoid receptor (prednisone); Cyclooxygenase-1 and Cyclooxygenase-2 (aspirin)
ketorolac (Acular LS)	ketorolac (Acular LS)	Center For Excellence In Eye Care	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Active ASA	Active ASA	Hamilton Health Sciences Corporation	marketed	Nonsteroidal Anti-Inflammatory Drug (NSAID)	Cyclooxygenase (COX) enzymes
Diclofenac oral + Placebo Oral	Diclofenac oral + Placebo Oral	Hospital de Clinicas de Porto Alegre	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Indomethacin suppository	Indomethacin suppository	Azienda USL Reggio Emilia - IRCCS	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class